TG Therapeutics (TGTX) Tmuɣli n wazal
Ṛṛbem n lḥedd$57.44Yettwalemmaḍ 25 Sep 2026 19:59 UTC
Beddel-0.12%
Asnulfu n AI: TGTX
AI tessawal ɣef timaqsiṭ n wazal i wass n tnekkit d-iteddun, taggara n yimal akked taggara n waggʷas. Asnifel yettwamḍen seg wazal aneggaru. Aya d tinineḍ n tḥisabt, ma tga ara timsisi n usihel.
Asref n 6 isggʷasn ineggura
Premium tessaɣ-d iswiyat n tɣara n AI i wass, amalas d waggʷas n yiwen i uḍris-a akk d yisɣunan niḍen.
Serreḥ Premium🔒 Tazmilt n usenfar
Amezruy n tmuɣliyin — akk tmuɣliyin n zik akked wazal n tnekkit — d akcum n Premium.
Serreḥ PremiumƔef tneɣlaft-a
TG Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the acquisition, development, and commercialization of innovative pharmaceutical products for the treatment of cancer and other underserved diseases. The company is developing two treatments for hematologic malignancies, specifically relapsed and refractory non-Hodgkin lymphoma.
